Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis

被引：4

作者：

Ludwig, Catherine M. ^{[1
]}

Hsiao, Jennifer L. ^{[2
]}

Lio, Peter A. ^{[3
,4
]}

Shi, Vivian Y. ^{[5
]}

机构：

[1] Univ Illinois, Coll Med, Chicago, IL 60680 USA

[2] Univ Calif Los Angeles, Div Dermatol, Dept Med, Los Angeles, CA USA

[3] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA

[4] Med Dermatol Associates Chicago, Chicago, IL USA

[5] Univ Arkansas Med Sci, Dept Dermatol, Little Rock, AR USA

来源：

DERMATITIS | 2021年 / 32卷 / 1S期

关键词：

GUIDELINES; ADULTS;

D O I：

10.1097/DER.0000000000000690

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically-tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.

引用

页码：S4 / S7

页数：4

共 19 条

[11]

LEO Pharma, 2019, TRAL MON AD SUBJ MOD

[12] A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis [J].

Ludwig, Catherine M. ;

Krase, Jeffrey M. ;

Price, Kyla N. ;

Lio, Peter A. ;

Shi, Vivian Y. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (05) :503-506

[13]

Novartis, NEOR CYCL PACK INS

[14] Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial [J].

Paller, Amy S. ;

Siegfried, Elaine C. ;

Thaci, Diamant ;

Wollenberg, Andreas ;

Cork, Michael J. ;

Arkwright, Peter D. ;

Gooderham, Melinda ;

Beck, Lisa A. ;

Boguniewicz, Mark ;

Sher, Lawrence ;

Weisman, Jamie ;

O'Malley, John T. ;

Patel, Naimish ;

Hardin, Megan ;

Graham, Neil M. H. ;

Ruddy, Marcella ;

Sun, Xian ;

Davis, John D. ;

Kamal, Mohamed A. ;

Khokhar, Faisal A. ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Beazley, Bethany ;

Bansal, Ashish ;

Shumel, Brad .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) :1282-1293

[15] Guidelines of care for the management of atopic dermatitis [J].

Sidbury, Robert ;

Davis, Dawn M. ;

Cohen, David E. ;

Cordoro, Kelly M. ;

Berger, Timothy G. ;

Bergman, James N. ;

Chamlin, Sarah L. ;

Cooper, Kevin D. ;

Feldman, Steven R. ;

Hanifin, Jon M. ;

Krol, Alfons ;

Margolis, David J. ;

Paller, Amy S. ;

Schwarzenberger, Kathryn ;

Silverman, Robert A. ;

Simpson, Eric L. ;

Tom, Wynnis L. ;

Williams, Hywel C. ;

Elmets, Craig A. ;

Block, Julie ;

Harrod, Christopher G. ;

Begolka, Wendy Smith ;

Eichenfield, Lawrence F. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (02) :327-349

[16] Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial [J].

Simpson, Eric L. ;

Paller, Amy S. ;

Siegfried, Elaine C. ;

Boguniewicz, Mark ;

Sher, Lawrence ;

Gooderham, Melinda J. ;

Beck, Lisa A. ;

Guttman-Yassky, Emma ;

Pariser, David ;

Blauvelt, Andrew ;

Weisman, Jamie ;

Lockshin, Benjamin ;

Hultsch, Thomas ;

Zhang, Qin ;

Kamal, Mohamed A. ;

Davis, John D. ;

Akinlade, Bolanle ;

Staudinger, Heribert ;

Hamilton, Jennifer D. ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Stahl, Neil ;

Yancopoulos, George D. ;

Ruddy, Marcella ;

Bansal, Ashish .

JAMA DERMATOLOGY, 2020, 156 (01) :44-56

[17]

Tofte S., 1998, J Eur Acad Dermatol Venereol, VS2, DOI [10.1016/S0926-9959(98)95291-6, DOI 10.1016/S0926-9959(98)95291-6]

[18] Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partII [J].

Wollenberg, A. ;

Barbarot, S. ;

Bieber, T. ;

Christen-Zaech, S. ;

Deleuran, M. ;

Fink-Wagner, A. ;

Gieler, U. ;

Girolomoni, G. ;

Lau, S. ;

Muraro, A. ;

Czarnecka-Operacz, M. ;

Schaefer, T. ;

Schmid-Grendelmeier, P. ;

Simon, D. ;

Szalai, Z. ;

Szepietowski, J. C. ;

Taieb, A. ;

Torrelo, A. ;

Werfel, T. ;

Ring, J. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (06) :850-878

[19] Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis [J].

Yosipovitch, G. ;

Reaney, M. ;

Mastey, V. ;

Eckert, L. ;

Abbe, A. ;

Nelson, L. ;

Clark, M. ;

Williams, N. ;

Chen, Z. ;

Ardeleanu, M. ;

Akinlade, B. ;

Graham, N. M. H. ;

Pirozzi, G. ;

Staudinger, H. ;

Plaum, S. ;

Radin, A. ;

Gadkari, A. .

BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (04) :761-769

← 1 2 →